Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).

Inclusion Criteria:

• Clinical diagnosis of moderate to severe Alzheimer's disease;
• ambulatory patients

Exclusion Criteria:

• folate deficiency;
• clinically significant central nervous system disease other than Alzheimer's disease;
• clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease